A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

Not Applicable

Completed

• Conditions: Diarrhea; HIV Infections

• Registration Number: NCT00002252
• Lead Sponsor: Sandoz

Brief Summary

To determine the efficacy and safety of Sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented HIV infection and which is refractory (does not respond) to all known treatment classes.

Detailed Description

Not available

Study Timeline

• Status Verified: 1992-08
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (23)

USC School of Medicine; 🇺🇸 Los Angeles, California, United States

UCSD Med Ctr; 🇺🇸 San Diego, California, United States

UCSF - San Francisco Gen Hosp; 🇺🇸 San Francisco, California, United States

Kaiser Permanente Med Ctr; 🇺🇸 San Francisco, California, United States

San Mateo County Gen Hosp; 🇺🇸 San Mateo, California, United States

Med Service; 🇺🇸 Miami, Florida, United States

Emory Univ School of Medicine; 🇺🇸 Atlanta, Georgia, United States

Rush Presbyterian - Saint Luke's Med Ctr; 🇺🇸 Chicago, Illinois, United States

Maine Med Ctr Med Clinics; 🇺🇸 Portland, Maine, United States

Douglas Plesko; 🇺🇸 Boston, Massachusetts, United States

Scroll for more (13 remaining)